Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 0963 • ACR Convergence 2021
Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRDs)
Gordon Lam¹, Andrew Laster², Sarah McCarter², Heather Gladue³, Ahmad Kashif², Erin Siceloff², Victoria Lackey³, Cheryl Robertson³, Ashley Toci² and Leonard Calabrese⁴, ¹Arthritis and Osteoporosis Consultants of the Carolinas, Cornelius, NC, ²Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ³Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ⁴Cleveland Clinic, Cleveland, OH
Background/Purpose: AIIRD patients may have a blunted immune response to the COVID-19 vaccines, but this is largely uncharacterized as these individuals were not included in…
Abstract Number: 1349 • ACR Convergence 2021
Joint-specific Responses to Tofacitinib and Adalimumab in Patients with Psoriatic Arthritis: Post Hoc Analysis of a Phase 3 Study
Adrian Ciurea¹, Tim Killeen², Raphael Micheroli¹, Norina N Gassman², Hyejin Jo³, Kenneth Kwok⁴, Elizabeth Kudlacz⁴, Oliver Distler¹, Caroline Ospelt⁵ and Mojca Frank-Bertoncelj¹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, ²Pfizer AG, Zurich, Switzerland, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, New York, NY, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Peripheral joint involvement in PsA varies. In RA, varied joint involvement may reflect site-specific differences in stromal cell transcriptome, including Janus kinase-signal transducer and…
Abstract Number: 1684 • ACR Convergence 2021
Incidence of Infections in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Andra R Bălănescu¹, Gustavo Citera², Virginia Pascual-Ramos³, Carol A Connell⁴, David Gold⁵, All-shine Chen⁴, Harry Shi⁶, Andrea B Shapiro⁷, Janet Pope⁸ and Hendrik Schulze-Koops⁹, ¹“Carol Davila” University of Medicine and Pharmacy, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Montréal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Peapack, NJ, ⁸University of Western Ontario, London, ON, Canada, ⁹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany
Background/Purpose: Previous clinical trial and real-world data suggest that risk of serious infection events (SIEs) and opportunistic infections (OIs) is similar with tofacitinib 5 mg…
Abstract Number: 1941 • ACR Convergence 2021
The Risk of Venous Thromboembolic Events in Patients with RA Aged ≥ 50 Years with ≥ 1 Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Christina Charles-Schoeman¹, Roy Fleischmann², Eduardo Mysler³, Maria Greenwald⁴, Cunshan Wang⁵, All-shine Chen⁵, Carol A Connell⁵, John C Woolcott⁶, Sujatha Menon⁵, Yan Chen⁷, Kristen Lee⁷ and Zoltan Szekanecz⁸, ¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY, ⁸Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary
Background/Purpose: ORAL Surveillance (NCT02092467) was a randomized, open-label, non-inferiority, Phase 3b/4 study that assessed the relative risk of major adverse cardiovascular (CV) events (MACE) and…
Abstract Number: 0206 • ACR Convergence 2021
Hydroxycloroquine-Induced Atrioventricular Block in Inmune-Mediated Diseases. Single University Center Study of 293 Patients
Alba Herrero-Morant¹, Adrián Margarida-de Castro¹, Raquel Pérez-Barquín², Jon Zubiaur-Zamacola¹, Miguel Ángel gonzalez-Gay³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Hydroxychloroquine (HCQ) is an extensively used drug in immune-mediated diseases (IMID). Despite its general safety, HCQ can cause serious toxicity such as heart conduction…
Abstract Number: 0809 • ACR Convergence 2021
The Impact of Flares on Clinical and Patient Reported Outcomes in Rheumatoid and Undifferentiated Arthritis Patients
Johanna Maria Maassen¹, Sytske Anne Bergstra¹, PDM de Buck², Maikel van Oosterhout³, Cornelia F. Allaart¹ and Tom WJ Huizinga¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Haaglanden medical center, The Hague, Netherlands, ³Groene Hart Hospital, Gouda, Netherlands
Background/Purpose: There are many definitions of flare in rheumatoid arthritis (RA). Loss of low disease activity is associated with clinically relevant deterioration. Patients in DAS…
Abstract Number: 0974 • ACR Convergence 2021
Use of Disease-Modifying Anti-Rheumatic Drug Associated with Lower Incidence of Anti-Tumor Necrosis Factor Induced Psoriasis in Children with Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis
Katelyn Baggett¹, Timothy Brandon¹, Rui Xiao², Zachary Valenzuela¹, Lisa Buckley³ and Pamela Weiss¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Vanderbilt Children's Hospital, Nashville, TN
Background/Purpose: Tumor necrosis factor inhibiting (TNFi) therapies are associated with new-onset psoriasis in children with inflammatory bowel disease (IBD) and juvenile idiopathic arthritis (JIA). We…
Abstract Number: 1352 • ACR Convergence 2021
Deucravacitinib Efficacy in Psoriatic Arthritis (PsA) by Baseline DMARD Use: Exploratory Analysis from a Phase 2 Study
Atul Deodhar¹, Miroslawa Nowak², June Ye², Tom Lehman², Lan Wei², Subhashis Banerjee² and Philip Mease³, ¹Oregon Health & Science University, Portland, OR, ²Bristol Myers Squibb, Princeton, NJ, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: PsA presents with heterogeneous clinical manifestations including joint pain, enthesitis, dactylitis, and skin and nail lesions. Treatment guidelines recommend that PsA patients (pts) who…
Abstract Number: 1693 • ACR Convergence 2021
Lower Adverse Event and Infection Rates During Tocilizumab Therapy Without Concomitant GC: An Analysis of the ICHIBAN Study
Christof Specker¹, Martin Aringer², Gerd Burmester³, Marvin A. Peters⁴, Michael W. Hofmann⁵, Herbert Kellner⁶, Frank Moosig⁷, Hans-Peter Tony⁸ and Gerhard Fliedner⁹, ¹Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, ²Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, ³Charité University Medicine Berlin, Berlin, Germany, ⁴Roche Pharma AG, Grenzach-Wyhlen, Germany, ⁵Chugai Pharma Germany GmbH, Frankfurt am Main, Germany, ⁶Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, Munich, Germany, ⁷Rheumatology Center Schleswig-Holstein Middle, Neumünster, Germany, ⁸Universitätsklinikum Würzburg, Wuerzburg, Germany, ⁹Rheumatology Practice, Osnabrueck, Germany
Background/Purpose: To limit the risk of serious infections, guidelines recommend short term (< 3 months) or low-dose (≤10 mg/day) adjunct glucocorticoids (GCs) to control rheumatoid…
Abstract Number: 1942 • ACR Convergence 2021
Occurrence of Basal Cell and Squamous Cell Carcinomas of the Skin Under Different DMARD Therapies
Imke Redeker¹, Peter Herzer², Cornelia Kühne³, Ilka Schwarze⁴, Martin Schaefer⁵ and Anja Strangfeld⁶, ¹German Rheumatism Research Centre (DRFZ), Berlin, Germany, ²Scientific Advisory Board, Munich, Germany, ³Rheumatologist, Haldensleben, Germany, ⁴Rheumatologist, Leipzig, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
Background/Purpose: Squamous and basal cell carcinomas are the most common malignancies of the skin; they are subsumed under non-melanoma skin cancer (NMSC). The risk of…
Abstract Number: 0261 • ACR Convergence 2021
Methotrexate Withdrawal and Outcomes in Participants with Well-controlled Non-systemic JIA Within the CARRA Registry
Marinka Twilt¹, Kevin Baszis², Sarah Ringold³, Timothy Beukelman⁴, Anne Dennos⁵, Peter Shrader⁶ and Daniel Horton⁷, ¹Alberta Children's Hospital, Calgary, AB, Canada, ²Washington University School of Medicine, St Louis, MO, ³Seattle Children's Hospital, Seattle, WA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Duke University, Durham, NC, ⁶Duke Clinical Research Institute, Durham, NC, ⁷Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Methotrexate (MTX) is currently the recommended first-line conventional DMARD for the treatment of JIA with oligo- or polyarthritis. There are limited data on how…
Abstract Number: 0814 • ACR Convergence 2021
Patient Characteristics, Efficacy, and Treatment Patterns of Tofacitinib Monotherapy in Patients with RA: Contextualization of Randomized Controlled Trial Results with Real-world Data
Janet Pope¹, Axel Finckh², Lucia Silva-Fernández³, Peter Mandl⁴, Haiyun Fan⁵, Jose L Rivas⁶, Monica Valderrama⁶ and María Montoro⁶, ¹University of Western Ontario, London, ON, Canada, ²University Hospital of Geneva, Geneve - Vesenaz, Switzerland, ³Hospital Universitari Son Espases, Palma de Mallorca, Spain, ⁴Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer SLU, Madrid, Spain
Background/Purpose: Randomized controlled trials (RCTs) have long been considered the gold standard for clinical research, but can be complemented with real-world data (RWD) to further…
Abstract Number: 0980 • ACR Convergence 2021
Relationship Between Paraoxonase-1 Genotype, Activity, and Malignancies in Patients with RA Receiving Tofacitinib
Christina Charles-Schoeman¹, Craig Hyde², Shunjie Guan³, Neil Parikh¹, Jennifer Wang¹, Ani Shahbazian¹, Lori Stockert⁴ and John Andrews⁴, ¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Cambridge, MA, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Paraoxonase-1 (PON1) is a high-density lipoprotein-associated enzyme with paraoxonase, lactonase, and arylesterase activities.1 PON1 gene polymorphisms at the Q192R allele (rs662) have been associated…
Abstract Number: 1442 • ACR Convergence 2021
Effectiveness of Cycling JAKi Compared to Switching to bDMARD in Patients Who Failed a First JAKi in an International Collaboration of Registries of Rheumatoid Arthritis Patients (the JAK-pot Study)
Manuel Pombo-Suarez¹, Carlos Sanchez-Piedra², Juan J Gomez-Reino³, Kim Lauper⁴, Nevsun Inanc⁵, Anja Strangfeld⁶, Doreen Huschek⁷, Karel Pavelka⁸, Eirik Kristianslund⁹, Tore Kvien¹⁰, Ziga Rotar¹¹, Dan Nordström¹², Denis Choquette¹³, Ori Elkayam¹⁴, Burkhard Leeb¹⁵, Maria José Santos¹⁶, Kimme Hyrich¹⁷, Lianne Kearsley-Fleet¹⁸, Catalin Codreanu¹⁹, Denis Monguin²⁰, Delphine Courvoisier²⁰ and Axel Finckh²¹, ¹Rheumatology Service, Hospital Clinico Universitario, Santiago De Compostela, Santiago de Compostela, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Hospital Clínico Universitario, Santiago de Compostela, Spain, ⁴Geneva University Hospitals, Geneve, Switzerland, ⁵Division of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁶Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁷Epidemiology and Health Services Research, German Rheumatism Research Center, Berlin, Germany, Berlin, Germany, ⁸Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁹Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ¹⁰Diakonhjemmet Hospital, Oslo, Norway, ¹¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, ¹²Division of Internal Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland, ¹³Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ¹⁴Tel Aviv Medical Center, Tel Aviv, Israel, ¹⁵Karl Landsteiner University for Health Sciences, Krems/Donau, Karl Landsteiner Institute for Clinical Rheumatology, Hollabrunn, Austria, ¹⁶Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, ¹⁷University of Manchester, Manchester, United Kingdom, ¹⁸Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹⁹Center of Rheumatic Diseases, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania, ²⁰Division of Rheumatology, Geneva University Hospital, Geneva, Switzerland, ²¹University Hospital of Geneva, Geneve - Vesenaz, Switzerland
Background/Purpose: With the arrival of new Janus kinase inhibitors (JAKi), with different JAK inhibition profiles, there is the possibility of using a second JAKi in…
Abstract Number: 1694 • ACR Convergence 2021
Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs
Ronald van Vollenhoven¹, Stephen Hall², Alvin Wells³, Sebastian Meerwein⁴, Yanna Song⁵, Jessica Suboticki⁵ and Roy Fleischmann⁶, ¹Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²Emeritus Research and Monash University, Melbourne, Australia, Melbourne, Australia, ³Rheumatology and Immunotherapy Center, Franklin, WI, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁵AbbVie Inc., North Chicago, IL, ⁶Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Sustained clinical remission (REM) is the primary treatment goal for patients with rheumatoid arthritis (RA), with low disease activity (LDA) being an appropriate target…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].